Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.

Experts discuss the implications of the FDA’s potential pathway to expand testosterone replacement therapy labeling for low libido in men with idiopathic hypogonadism.

LUGPA CEO Celeste Kirschner, CAE, MHSA, outlines the association's top 2027 priorities: fee schedule reform, site-neutral payments, prior authorization, and practice consolidation.

"If a high percentage of the radicals are billed with urethral suspension, then it is likely to be bundled in the future and it is possible that it will be tagged with an indicator that will not allow ...

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP ...

"The patient’s counsel alleged that the urologist had failed to properly inform the patient of the risks and complications associated with the treatment," writes Acacia Brush Perko, Esq. On August 22, ...

The ZIRCON trial reported high accuracy of TLX250-CDx in detecting and characterizing ccRCC in patients with indeterminate renal masses. Data from the phase 3 ZIRCON trial (NCT03849118) evaluating ...

Although the overall incidence of prostate cancer has declined, the percentage of patients with metastatic disease at diagnosis has increased over the last decade. Over the past decade, the incidence ...

One factor is whether dissection was performed for staging or for therapeutic purposes. It really comes down to the extent of the lymph node dissection and the work that was done and whether the lymph ...

The TOBY Test uses AI and gas chromatography–mass spectrometry to analyze urine for early cancer detection, offering a significant advantage over current methods. The FDA's breakthrough device ...

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

Challenge is presented by switching from SWL to ureteroscopy intraoperatively. I’m looking for some guidance on a couple of stone case scenarios. Both scenarios have to do with shock wave lithotripsy ...